459 related articles for article (PubMed ID: 21215653)
1. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
Mercadante S
Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
[TBL] [Abstract][Full Text] [Related]
2. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
3. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
4. Managing breakthrough pain.
Mercadante S
Curr Pain Headache Rep; 2011 Aug; 15(4):244-9. PubMed ID: 21424673
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy for breakthrough cancer pain.
Mercadante S
Drugs; 2012 Jan; 72(2):181-90. PubMed ID: 22233484
[TBL] [Abstract][Full Text] [Related]
6. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
Mercadante S
Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
[TBL] [Abstract][Full Text] [Related]
8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
9. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
10. Recent development in therapeutics for breakthrough pain.
Davis MP
Expert Rev Neurother; 2010 May; 10(5):757-73. PubMed ID: 20420495
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
Jandhyala R; Fullarton JR; Bennett MI
J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
[TBL] [Abstract][Full Text] [Related]
12. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Dietrich E; Gums JG
Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
[TBL] [Abstract][Full Text] [Related]
15. Treating breakthrough pain in oncology.
Mercadante S
Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
17. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
Fine PG; Narayana A; Passik SD
Pain Med; 2010 Jul; 11(7):1024-36. PubMed ID: 20642730
[TBL] [Abstract][Full Text] [Related]
18. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.
Zeppetella G; Davies A; Eijgelshoven I; Jansen JP
J Pain Symptom Manage; 2014 Apr; 47(4):772-785.e5. PubMed ID: 23981487
[TBL] [Abstract][Full Text] [Related]
19. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
Romualdi P; Candeletti S
Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
[TBL] [Abstract][Full Text] [Related]
20. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
